Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: A network meta-analysis

The Lancet

Volumn 385, Issue 9982, 2015, Pages 2047-2056

  Palmer, Suetonia C ^a   Mavridis, Dimitris ^b,c   Navarese, Eliano ^d   Craig, Jonathan C ^e   Tonelli, Marcello ^f   Salanti, Georgia ^b   Wiebe, Natasha ^g   Ruospo, Marinella ^h,i   Wheeler, David C ^k   Strippoli, Giovanni F M ^e,i,j  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF IOANNINA   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

^d NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^e UNIVERSITY OF SYDNEY   (Australia)

^f UNIVERSITY OF CALGARY   (Canada)

^g UNIVERSITY OF ALBERTA   (Canada)

^h UNIVERSITY OF EASTERN PIEDMONT   (Italy)

ⁱ Diaverum Medical Scientific Office   (Sweden)

^j UNIVERSITY OF BARI   (Italy)

^k ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; PLACEBO; RENIN INHIBITOR;

ACUTE KIDNEY FAILURE; ARTICLE; CHRONIC KIDNEY DISEASE; COMPARATIVE EFFECTIVENESS; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; END STAGE RENAL DISEASE; HUMAN; HYPERKALEMIA; KIDNEY DISEASE; META ANALYSIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84930077401     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)62459-4     Document Type: Article

References (36)

1. S Wild, G Roglic, A Green, R Sicree, H King Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 27 2004 1047 1053
2. E Ritz, SR Orth Nephropathy in patients with type 2 diabetes mellitus N Engl J Med 341 1999 1127 1133
3. US Renal Data System 2013 atlas of CKD and ESRD http://www.usrds.org/atlas.aspx 2013 (accessed Dec 5, 2014).
4. RN Foley, AM Murray, S Li et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999 J Am Soc Nephrol 16 2005 489 495
5. NR Burrows, Y Li, LS Geiss Incidence of treatment for end-stage renal disease among individuals with diabetes in the US continues to decline Diabetes Care 33 2010 73 77
6. GF Strippoli, M Craig, JJ Deeks, FP Schena, JC Craig Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review BMJ 329 2004 828
7. Kidney Disease Improving Global Outcomes KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease: chapter 4 - blood pressure management in CKD ND patients with diabetes mellitus Kidney Int Suppl 2 2012 363 369
8. PA James, S Oparil, BL Carter et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) JAMA 311 2014 507 520
9. LF Fried, N Emanuele, JH Zhang et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy N Engl J Med 369 2013 1892 1903
10. JF Mann, RE Schmieder, M McQueen on behalf of the ONTARGET investigators Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial Lancet 372 2008 547 553
11. HJ Lambers Heerspink, D de Zeeuw ONTARGET still OFF-TARGET? Circulation 123 2011 1049 1051
12. H-Y Wu, J-W Huang, H-J Lin et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and Bayesian network meta-analysis BMJ 347 2013 f6008
13. D Moher, A Liberati, J Tetzlaff, DG Altman Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement J Clin Epidemiol 62 2009 1006 1012
14. Kidney Disease Improving Global Outcomes KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease: chapter 1 - definition and classification of CKD Kidney Int Suppl 3 2013 1 150
15. JPT Higgins, S Green Cochrane handbook for systematic reviews of interventions, version 5.1.0 http://www.cochrane-handbook.org March, 2011 (accessed April 9, 2015).
16. R DerSimonian, N Laird Meta-analysis in clinical trials Clin Trials 7 1986 177 188
17. G Salanti Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool Res Synth Methods 3 2012 80 97
18. RM Turner, J Davey, MJ Clarke, SG Thompson, JP Higgins Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews Int J Epidemiol 41 2012 818 827
19. G Salanti Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool Res Synth Methods 3 2012 80 97
20. G Salanti, V Marinho, JP Higgins A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered J Clin Epidemiol 62 2009 857 864
21. AA Veroniki, HS Vasiliadis, JP Higgins, G Salanti Evaluation of inconsistency in networks of interventions Int J Epidemiol 42 2013 332 345
22. JPT Higgins, D Jackson, JK Barrett, G Lu, AE Ades, IR White Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies Res Synth Methods 3 2012 98 110
23. G Salanti, AE Ades, JP Ioannidis Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial J Clin Epidemiol 64 2011 163 171
24. IR White, JK Barrett, D Jackson, JP Higgins Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression Res Synth Methods 3 2012 111 125
25. A Chaimani, JP Higgins, D Mavridis, P Spyridonos, G Salanti Graphical tools for network meta-analysis in STATA PLoS One 8 2013 e76654
26. Multiple Treatments Meta-Analysis Using STATA for network meta-analysis http://www.mtm.uoi.gr/index.php/stata-routines-for-network-meta-analysis March 11, 2015 (accessed April 8, 2015).
27. JR Ingelfinger A new era for the treatment of hyperkalemia? N Engl J Med 372 2015 275 277
28. DK Packham, HS Rasmussen, PT Lavin et al. Sodium zirconium cyclosilicate in hyperkalemia N Engl J Med 372 2015 222 231
29. MR Weir, GL Bakris, DA Bushinsky et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors N Engl J Med 372 2015 211 221
30. EJ Lewis, LG Hunsicker, RP Bain, RD Rohde for the Collaborative Study Group The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy N Engl J Med 329 1993 1456 1462
31. M Ravid, R Lang, R Rachmani, M Lishner Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study Arch Intern Med 156 1996 286 289
32. National Institute of Health National Heart Lung and Blood Institute The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: NIH publication no 98-4080 http://www.nhlbi.nih.gov/health-pro/guidelines/archive/hypertension-jnc6 November, 1997 (accessed April 9, 2015).
33. National Institute of Health National Heart Lung and Blood Institute The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: NIH publication no 04-5230 http://www.nhlbi.nih.gov/files/docs/guidelines/jnc7full.pdf August, 2004 (accessed April 9, 2015).
34. National Kidney Foundation Kidney Disease Outcomes Quality Initiative Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease 2004 Available at http://www2.kidney.org/professionals/KDOQI/guidelines-bp/ (accessed April 9, 2015).
35. JF Mann, D Green, K Jamerson et al. Avosentan for overt diabetic nephropathy J Am Soc Nephrol 21 2010 527 535
36. A Maione, SD Navaneethan, G Graziano et al. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials Nephrol Dial Transplant 26 2011 2827 2847